Stallergenes Greer’s Personalised Allergen Immunotherapy Model Encouraged by Leading Scientists: "Allergy" Journal Publishes Article Today
Stallergenes Greer, a biopharmaceutical company specialising in treatments for allergies, announces the publication of an article titled “Personalized Medicine for allergy treatment: AIT, still a unique and unmatched model” in the EAACI’s (European Academy of Allergy and Clinical Immunology) official journal Allergy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005819/en/
The publication marks a clear consensus on allergen immunotherapy (AIT). It was co-authored by 49 world-renowned allergy specialists from 40 countries and coordinated by Professor Giorgio Walter Canonica, Personalised Medicine, Asthma and Allergy, Humanitas University and Research (Milano, Italy) and Professor Cristoforo Incorvaia, Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, (Milano, Italy), with an unrestricted grant from Stallergenes Greer.
The article demonstrates that there is very strong evidence to show that AIT achieves its primary therapeutic goals in patients with respiratory allergies1,2 by reducing the frequency and intensity of symptoms, the use of rescue medications, and improving quality of life for people with allergies.
Personalised medicine is improving the effectiveness and precision of allergy diagnosis and consequently increasing the performance and treatment outcome of AIT.
“This landmark publication, which is fully aligned with Stallergenes Greer’s commitment, highlights the unique role of AIT in allergy treatment encompassing the prediction of a successful treatment, the potential prevention or progression of an allergic disease, and the possibility of providing such advances at affordable costs, ” states Amer Jaber, EVP Operations Europe and President of Stallergenes SAS, who heads Stallergenes Greer's R&D.
AIT: a medical model of personalised healthcare
The article outlines that personalised allergy care is valuable and may also be preventive by focusing on quality of life, predictive by allowing treatment to be adjusted to the individual’s response and participative by empowering the patient.
AIT is consistent with the three major needs to be met in personalised medicine:
- the identification of the molecular mechanism of the disease,
- the availability of diagnostic tools to recognise this mechanism, and
- the availability of a treatment capable of blocking the mechanism3,4.
AIT delivers customised healthcare, with medical decisions, practices, and/or products tailored to the individual patient5 .
Leveraging precision medicine for personalised allergy care
This tailor-made approach to diagnosis, decision-making, product choice and treatment schedules may enhance effectiveness, minimise adverse events, improve quality of life and reduce the socio-economic impact of allergies 6,7,8,9.
Stallergenes Greer’s purpose “Enabling precision medicine to improve life for people with allergies” is in line with the statements set out in the article. Stallergenes Greer is committed to furthering precision medicine and personalised AIT treatments to maximise treatment outcomes for patients with allergies.
Read the full article here: https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14575
ABOUT STALLERGENES GREER Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Additional information is available at: https://www.stallergenesgreer.com/
Roberts G, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis.
2 Demoly P, et al. The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment. J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):640-648.
3 Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010: 22; 363(4):301-4.
4 Passalacqua G, Canonica GW. AIT (allergen immunotherapy): a model for the "precision medicine". Clin Mol Allergy. 2015: 8;13:24.
5 Canonica GW, et al. Allergen Immunotherapy (AIT): A prototype of precision medicine. World Allergy Organ J. 2015;8 (1), 31 2015.
6 Gueguen C, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. J Allergy Clin Immunol. 2016; 137:545-558.
7 Caillot N, et al. Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy. J Allergy Clin Immunol. 2017;140; 759-770.
8 Gueguen C, et al. IL-10 mRNA levels in whole blood cells correlate with house dust mite allergen immunotherapy efficacy. Allergy. 2019; 74:2223-2226.
9 Luce S, et al. Th2A and Th17 cell frequencies and regulatory markers as follow-up biomarker candidates for successful multifood oral immunotherapy. Allergy. 2020; 75:1513-1516.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-C3.AI-DTI4.3.2021 20:02:12 CET | Press release
C3.ai Digital Transformation Institute Announces Shell as New Industry Partner
NC-DOLE-FOOD-COMPANY4.3.2021 19:24:10 CET | Press release
Dole Launches “The Dole Way” Sustainability Campaign
SC-MILLIKEN-&-COMPANY4.3.2021 18:02:06 CET | Press release
Milliken & Company Appoints Cindy Boiter as Executive Vice President, Chemical Division President
CA-VERIMATRIX4.3.2021 17:47:15 CET | Press release
Verimatrix Takes Home Two 2021 Gold Cybersecurity Excellence Awards
MEDICORTEX4.3.2021 15:10:11 CET | Press release
Business Finland Awarded Funding for Medicortex
NV-RIMINI-STREET,-INC.4.3.2021 15:07:10 CET | Press release
Kent County Council Switches to Rimini Street Support for its Oracle Applications and Database Software
TX-SCHLUMBERGER/CHEVRON4.3.2021 15:02:10 CET | Press release
Schlumberger New Energy, Chevron, and Microsoft Collaborate on Carbon Negative Bioenergy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom